Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

被引：0

作者：

Pietro Ciceri

Susanne Müller

Alison O'Mahony

Oleg Fedorov

Panagis Filippakopoulos

Jeremy P Hunt

Elisabeth A Lasater

Gabriel Pallares

Sarah Picaud

Christopher Wells

Sarah Martin

Lisa M Wodicka

Neil P Shah

Daniel K Treiber

Stefan Knapp

机构：

[1] KINOMEscan Division of DiscoveRx Corporation,Nuffield Department of Clinical Medicine

[2] University of Oxford,Nuffield Department of Clinical Medicine

[3] Structural Genomics Consortium,Nuffield Department of Clinical Medicine

[4] University of Oxford,Division of Hematology/Oncology

[5] Target Discovery Institute (TDI),undefined

[6] BioSeek Division of DiscoveRx Corporation,undefined

[7] University of Oxford,undefined

[8] Ludwig Institute for Cancer Research (LICR),undefined

[9] University of California–San Francisco,undefined

来源：

Nature Chemical Biology | 2014年 / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Kinases are a widely targeted enzyme class in cancer chemotherapy. Several clinically used kinase inhibitors also inhibit bromodomains, epigenetic ‘readers’ of acetylated lysine residues, suggesting that kinase-bromodomain polypharmacology may offer benefits in therapeutic settings.[graphic not available: see fulltext]

引用

页码：305 / 312

页数：7

共 50 条

[41] Large-Scale Evaluation of CavBase for Analyzing the Polypharmacology of Kinase Inhibitors
Kalliokoski, Tuomo
Vulpetti, Anna
MOLECULAR INFORMATICS, 2011, 30 (11-12) : 923 - 925
[42] Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors
Uckun, Fatih M.
Vassilev, Alexei
Dibirdik, Ilker
Tibbles, Heather
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (06) : 612 - 623
[43] Hsp90 Inhibitors from rationally designed chimeric compounds
Shen, Gang
Blagg, Brian S. J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
[44] Rationally designed TNF-α inhibitors: Identification of promising cytotoxic agents
Kaur, Baljit
Mishra, Sahil
Kaur, Ramandeep
Kalotra, Shikha
Singh, Palwinder
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 41
[45] Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model
Cetkovic-Cvrlje, M
Uckun, FM
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (06) : 821 - 827
[46] Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors
Karim, Rezaul Md
Bikowitz, Melissa J.
Chan, Alice
Zhu, Jin-Yi
Grassie, Dylan
Becker, Andreas
Berndt, Norbert
Gunawan, Steven
Lawrence, Nicholas J.
Schonbrunn, Ernst
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (21) : 15772 - 15786
[47] X-Ray crystallographic studies of rationally designed dihydroorotate dehydrogenase inhibitors
Acklam, Paul
Bedingfield, Paul
Cunningham, Fraser
Cowen, Deborah
McConkey, Glenn
Fishwick, Colin
Johnson, Peter
Parsons, Mark
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2011, 67 : C312 - C312
[48] Development of rationally designed DNA N6 adenine methyltransferase inhibitors
Hobley, Gerard
McKelvie, Jennifer C.
Harmer, Jenny E.
Howe, Jason
Oyston, Petra C. F.
Roach, Peter L.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (09) : 3079 - 3082
[49] Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Ember, Stuart W.
Lambert, Que T.
Berndt, Norbert
Gunawan, Steven
Ayaz, Muhammad
Tauro, Marilena
Zhu, Jin-Yi
Cranfill, Paula J.
Greninger, Patricia
Lynch, Conor C.
Benes, Cyril H.
Lawrence, Harshani R.
Reuther, Gary W.
Lawrence, Nicholas J.
Schonbrunn, Ernst
MOLECULAR CANCER THERAPEUTICS, 2017, 16 (06) : 1054 - 1067
[50] Rationally designed amyloid inhibitors based on amyloid-related structural studies
Hu, Jinjian
Zhao, Yufen
Li, Yanmei
CHINESE CHEMICAL LETTERS, 2023, 34 (02)

← 1 2 3 4 5 →